H.C. Wainwright reiterates Nektar Therapeutics stock rating on alopecia data Investing.com · News 11m ago
Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt Investing.com · News 11m ago
Guggenheim raises MBX Biosciences price target to $150 on obesity drug potential Investing.com · News 17m ago